As of September 27, 2023, Genmab A/S (NASDAQ:GMAB) has received a “Hold” consensus recommendation from the fifteen analysts that cover the stock, according to Bloomberg.com. Among these analysts, two have rated the stock as a sell, seven have given it a hold rating, and six have rated it as a buy. The average one-year price objective among analysts who have issued reports on the stock in the past year is $41.40.
On Wednesday, GMAB stock opened at $36.53. The company currently has a market capitalization of $24.13 billion and a PE ratio of 36.53. The price-to-earnings-growth ratio stands at 2.15 with a beta of 0.94. Over the past year, Genmab A/S has traded between a low of $31.40 and a high of $47.
Genmab A/S is primarily focused on developing antibody therapeutics for the treatment of cancer and other diseases in Denmark. One of its key products is DARZALEX, which is used as a human monoclonal antibody for multiple myeloma (MM) patients. It also offers teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis treatment, as well as Amivantamab for advanced gastric or esophageal cancer and non-small cell lung cancer (NSCLC).
The most recent earnings release from Genmab A/S was on August 3rd when the company reported an EPS of $0.30 for the quarter. This figure fell short of the consensus estimate by ($0.01), while generating revenue of $613.43 million compared to the predicted amount of $618.77 million from analysts’ estimates. The net margin for Genmab A/S during this period stood at 28.78%, with a return on equity of 16.93%. Research analysts, on average, predict that the company will post an EPS of 1.02 for the current year.
Overall, while Genmab A/S has received mixed ratings from research analysts, it remains a prominent player in developing antibody therapeutics for cancer and other diseases. Investors should closely monitor any advancements or updates regarding its product pipeline as they may significantly impact the stock’s performance.
Analyzing Genmab A/S: Research Analysts, Hedge Funds, and Institutional Investors Weigh In
In recent months, there has been a flurry of activity surrounding the Danish biotechnology company Genmab A/S. Numerous research analysts have shared their evaluations and recommendations concerning the company’s performance and stock ratings.
One such analyst is Royal Bank of Canada, which recently downgraded Genmab A/S from an “outperform” rating to a “sector perform” rating in a report released on September 6th, 2023. This change in rating reflects a shift in the bank’s perception of the company’s overall market performance and prospects.
Contrarily, BTIG Research initiated coverage on Genmab A/S with an optimistic outlook by giving it a “buy” rating on August 24th. The research note suggests that BTIG is confident in the company’s potential for growth and success in its respective industry.
HSBC also assumed coverage on Genmab A/S, providing it with a “buy” rating on July 14th. This indicates that HSBC believes the stock presents an attractive investment opportunity for its clients and highlights their faith in the company’s future performance.
However, not all research analysts share this positive sentiment towards the biotech firm. Morgan Stanley reissued an “underweight” rating on Genmab A/S shares on July 31st, signaling caution and concern over the company’s projected profitability compared to its peers.
Despite these mixed reviews from various experts in the field, hedge funds and institutional investors have shown interest in Genmab A/S. First Manhattan Co., for instance, recently purchased stakes in the company worth $26,000 during the fourth quarter of last year.
Parallel Advisors LLC increased its position by 54.8% during the second quarter, acquiring an additional 410 shares valued at $44,000. Similarly, Great West Life Assurance Co. Can saw a considerable rise of 69.0% during Q1 as it purchased an extra 649 shares worth $60,000.
Russell Investments Group Ltd. displayed a significant surge in stake ownership, reaching 14,836.4% during the second quarter. The firm now holds 1,643 shares valued at $62,000. Lastly, Atlas Capital Advisors LLC substantially expanded its holdings by 176.4% during the fourth quarter, investing in an additional 1,588 shares worth $105,000.
All these investments collectively amount to approximately 6.29% of Genmab A/S stock being owned by hedge funds and institutional investors. This level of interest from major players in the financial market indicates their confidence in Genmab A/S and their willingness to back its future growth and success.
As with any investment decision, it is crucial for investors to consider multiple perspectives and conduct thorough research before making conclusions regarding Genmab A/S’ stock performance and prospects moving forward. The diverse range of opinions expressed by research analysts and the actions taken by hedge funds and institutional investors demonstrate the complex atmosphere surrounding this biotech company as of September 27th, 2023.